[[New antibiotics series XIII]: BRL 25000 (clavulanic acid/amoxicillin)].
D000658:Amoxicillin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D002969:Clavulanic Acids / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010403:Penicillin Resistance
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D004338:Drug Combinations; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin